
What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them? Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies. This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of B...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

288: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 2

287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1

286: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 2

285: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 1
Free AI-powered recaps of Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.